363 research outputs found
Efficacy and safety of Polyquad-preserved Travoprost in Ocular Hypertensive and Open Angle Glaucoma Patients:an open label, observational, 6-month, switch study.
Six months study on signs and symptoms of polyquad preserved travoprost/timolol fixed combination on previously treated glaucoma patients.
HCV and diabetes: Towards a 'sustained' glycaemic improvement after treatment with DAAs?
We read with interest the paper by Pavone and colleagues [1]
describing the rapid reduction of fasting glucose (FG) levels in diabetic
hepatitis C virus (HCV)-positive patients receiving directacting
antiviral agents (DAAs).
We aimed to assess if a similar decreasing trend of FG levels
occurred in our study population and if it was maintained after the
end of treatment (EOT). Therefore, we retrospectively evaluated
449 patients treated with DAAs at our centre (64 HIV/HCV coinfected)
Colonisation with Extended-Spectrum Cephalosporin-Resistant Enterobacterales and Infection Risk in Surgical Patients: A Systematic Review and Meta-analysis
Introduction: Limited evidence has been reported for surgical site infections (SSIs) in patients undergoing surgery who are carriers of extended-spectrum cephalosporin-resistant Enterobacterales (ESCR-E). A systematic review and meta-analysis were conducted to evaluate the risk of postoperative infections in adult inpatients colonised with ESCR-E before surgery. Methods: The Medline, Embase and Cochrane databases were searched between January 2011 and April 2022, following PRISMA indications. Random effects meta-analysis was used to quantify the association between ESCR-E colonisation and infection. Results: Among the 467 articles reviewed, 9 observational studies encompassing 7219 adult patients undergoing surgery were included. The ESCR-E colonisation rate was 13.7% (95% CI 7.7–19.7). The most commonly reported surgeries included abdominal surgery (44%) and liver transplantation (LT; 33%). The SSI rate was 23.2% (95% CI 13.2–33.1). Pooled incidence risk was 0.36 (95% CI 0.22–0.50) vs 0.13 (95% CI 0.02–0.24) for any postoperative infection and 0.28 (95% CI 0.18–0.38) vs 0.17 (95% CI 0.07–0.26) for SSIs in ESCR-E carriers vs noncarriers, respectively. In ESCR-E carriers, the ESCR-E infection ratio was 7 times higher than noncarriers. Postoperative infection risk was higher in carriers versus noncarriers following LT. Sources of detected heterogeneity between studies included ESCR-E colonisation and the geographic region of origin. Conclusions: Patients colonised with ESCR-E before surgery had increased incidence rates of post-surgical infections and SSIs compared to noncarriers. Our results suggest considering the implementation of pre-surgical screening for detecting ESCR-E colonisation status according to the type of surgery and the local epidemiology
Espécies arbóreas de uso múltiplo em uma comunidade Makuxi no lavrado de Roraima, Amazônia brasileira.
Estudos etnobotânicos buscam resgatar o conhecimento botânico tradicional quanto ao uso e manejo dos recursos vegetais, enfatizando a participação de comunidades locais para melhor elaboração de estratĂ©gias de conservação. Desta forma, foi realizado um levantamento etnobotânico por meio de entrevistas semiestruturadas com 60 participantes (36 homens e 24 mulheres) de 38 famĂlias, entre 18 e 84 anos de idade na Comunidade IndĂgena Darora, etnia Makuxi, na Terra IndĂgena SĂŁo Marcos, aos quais os foram arguidos sobre as espĂ©cies arbĂłreas presentes na regiĂŁo e seus usos.TambĂ©m foi realizado um levantamento florĂstico e fitossociolĂłgico para verificar a disponibilidade dos recursos lenhosos. As respostas foram agrupadas nas categorias Alimentação (inclui Ração Animal), Artesanato, CombustĂvel, Construção, Medicinal e Tecnologia e as espĂ©cies tiveram seus valores de uso e parâmetros fitossociolĂłgicos calculados. Quatro espĂ©cies arbĂłreas apresentaram destaque na Comunidade mostrando ao menos em cinco das seis categorias, Cassia moschata Kunth (marimari), Copaifera pubiflora Benth. (copaĂba), Genipa americana L. (jenipapo) e Mauritia flexuosa L. f. (buriti). A copaĂba (Copaifera pubiflora) e o marimari (Cassia moschata) foram as Ăşnicas espĂ©cies associadas a todas as categorias de uso, embora ambas tenham se destacado principalmente na categoria Construção. Copaifera pubiflora tambĂ©m teve grande destaque na categoria Medicinal e o Cassia moschata na categoria Tecnologia. EspĂ©cies de uso mĂşltiplo na Comunidade Darora reconhecidas aqui chamaram a atenção pelos baixos valores de disponibilidade no ambiente. No entanto, destas espĂ©cies, Copaifera pubiflora e Mauritia flexuosa foram as que apresentaram maiores valores de uso, indicando um maior conhecimento e potencial uso pelos moradores
What is the impact of SARS-CoV-2 pandemic on antimicrobial stewardship programs (ASPs)? The results of a survey among a regional network of infectious disease centres
Discontinuation of antimicrobial stewardship programs (ASPs) and increased antibiotic use were described during SARS-CoV-2 pandemic. In order to measure COVID-19 impact on ASPs in a setting of high multidrug resistance organisms (MDRO) prevalence, a qualitative survey was designed. In July 2021, eighteen ID Units were asked to answer a questionnaire about their hospital characteristics, ASPs implementation status before the pandemic and impact of SARS-CoV-2 pandemic on ASPs after the 1st and 2nd pandemic waves in Italy. Nine ID centres (50%) reported a reduction of ASPs and in 7 cases (38.9%) these were suspended. After the early pandemic waves, the proportion of centres that restarted their ASPs was higher among the ID centres where antimicrobial stewardship was formally identified as a priority objective (9/11, 82%, vs 2/7, 28%). SARS-CoV-2 pandemic had a severe impact in ASPs in a region highly affected by COVID-19 and antimicrobial resistance but weaknesses related to the pre-existent ASPs might have played a role
Microstructural characterization of alkali metal mediated high temperature reactions in mullite based refractories
Hospital-Acquired Infections in Critically Ill Patients With COVID-19
Background: Few small studies have described hospital-acquired infections (HAIs) occurring in patients with COVID-19. Research Question: What characteristics in critically ill patients with COVID-19 are associated with HAIs and how are HAIs associated with outcomes in these patients? Study Design and Methods: Multicenter retrospective analysis of prospectively collected data including adult patients with severe COVID-19 admitted to eight Italian hub hospitals from February 20, 2020, through May 20, 2020. Descriptive statistics and univariate and multivariate Weibull regression models were used to assess incidence, microbial cause, resistance patterns, risk factors (ie, demographics, comorbidities, exposure to medication), and impact on outcomes (ie, ICU discharge, length of ICU and hospital stays, and duration of mechanical ventilation) of microbiologically confirmed HAIs. Results: Of the 774 included patients, 359 patients (46%) demonstrated 759 HAIs (44.7 infections/1,000 ICU patient-days; 35% multidrug-resistant [MDR] bacteria). Ventilator-associated pneumonia (VAP; n = 389 [50%]), bloodstream infections (BSIs; n = 183 [34%]), and catheter-related BSIs (n = 74 [10%]) were the most frequent HAIs, with 26.0 (95% CI, 23.6-28.8) VAPs per 1,000 intubation-days, 11.7 (95% CI, 10.1-13.5) BSIs per 1,000 ICU patient-days, and 4.7 (95% CI, 3.8-5.9) catheter-related BSIs per 1,000 ICU patient-days. Gram-negative bacteria (especially Enterobacterales) and Staphylococcus aureus caused 64% and 28% of cases of VAP, respectively. Variables independently associated with infection were age, positive end expiratory pressure, and treatment with broad-spectrum antibiotics at admission. Two hundred thirty-four patients (30%) died in the ICU (15.3 deaths/1,000 ICU patient-days). Patients with HAIs complicated by septic shock showed an almost doubled mortality rate (52% vs 29%), whereas noncomplicated infections did not affect mortality. HAIs prolonged mechanical ventilation (median, 24 days [interquartile range (IQR), 14-39 days] vs 9 days [IQR, 5-13 days]; P < .001), ICU stay (24 days [IQR, 16-41 days] vs 9 days [IQR, 6-14 days]; P = .003), and hospital stay (42 days [IQR, 25-59 days] vs 23 days [IQR, 13-34 days]; P < .001). Interpretation: Critically ill patients with COVID-19 are at high risk for HAIs, especially VAPs and BSIs resulting from MDR organisms. HAIs prolong mechanical ventilation and hospitalization, and HAIs complicated by septic shock almost double mortality. Trial Registry: ClinicalTrials.gov; No.: NCT04388670; URL: www.clinicaltrials.go
Response of an Italian reference institute to research challenges regarding a new pandemic: COVID-19 network
- …